Compare Stocks: ADAG, DSGN, RIGL, and CLYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$3.26 +1.6%	$3.66	$1.30 ▼ $4.85	$215.32M	0.56	233,025 shs	121,167 shs
CLYM Climb Bio	$13.91 +2.0%	$14.30	$1.54 ▼ $18.33	$798.42M	0.09	1.03 million shs	298,100 shs
DSGN Design Therapeutics	$13.04 +3.9%	$13.85	$5.28 ▼ $17.25	$816.54M	1.66	602,418 shs	135,120 shs
RIGL Rigel Pharmaceuticals	$48.07 +2.1%	$43.15	$24.95 ▼ $52.24	$889.20M	1.2	362,473 shs	58,931 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-3.02%	-1.83%	-20.15%	-19.35%	+56.59%
CLYM Climb Bio	-2.92%	-6.32%	-21.06%	+10.89%	+490.48%
DSGN Design Therapeutics	+2.53%	-7.17%	-16.28%	-8.66%	+107.44%
RIGL Rigel Pharmaceuticals	+0.96%	+3.84%	+2.61%	+32.24%	+35.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$3.26 +1.6%	$3.66	$1.30 ▼ $4.85	$215.32M	0.56	233,025 shs	121,167 shs
CLYM Climb Bio	$13.91 +2.0%	$14.30	$1.54 ▼ $18.33	$798.42M	0.09	1.03 million shs	298,100 shs
DSGN Design Therapeutics	$13.04 +3.9%	$13.85	$5.28 ▼ $17.25	$816.54M	1.66	602,418 shs	135,120 shs
RIGL Rigel Pharmaceuticals	$48.07 +2.1%	$43.15	$24.95 ▼ $52.24	$889.20M	1.2	362,473 shs	58,931 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-3.02%	-1.83%	-20.15%	-19.35%	+56.59%
CLYM Climb Bio	-2.92%	-6.32%	-21.06%	+10.89%	+490.48%
DSGN Design Therapeutics	+2.53%	-7.17%	-16.28%	-8.66%	+107.44%
RIGL Rigel Pharmaceuticals	+0.96%	+3.84%	+2.61%	+32.24%	+35.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.80	Moderate Buy	$8.67	166.58% Upside
CLYM Climb Bio	3.00	Buy	$26.92	95.35% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	28.16% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	23.42% Upside

Current Analyst Ratings Breakdown

Latest ADAG, DSGN, RIGL, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/10/2026	ADAG Adagene	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$7.67M	28.00	N/A	N/A	$0.75 per share	4.33
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
RIGL Rigel Pharmaceuticals	$294.28M	3.01	$6.91 per share	6.92	$21.57 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.94	11.07	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest ADAG, DSGN, RIGL, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	5.02	3.07
CLYM Climb Bio	N/A	31.45	31.45
DSGN Design Therapeutics	N/A	18.86	18.86
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
CLYM Climb Bio	69.76%
DSGN Design Therapeutics	56.64%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
CLYM Climb Bio	2.60%
DSGN Design Therapeutics	17.10%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	128	66.05 million	52.05 million	Not Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable

ADAG, DSGN, RIGL, and CLYM Headlines

Recent News About These Companies

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 20 at 4:44 AM | americanbankingnews.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages

September 20 at 4:43 AM | marketbeat.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

September 15, 2026 | seekingalpha.com

Rigel Pharmaceuticals op H.C. Wainwright-conferentie: groeiplan verbreed

September 15, 2026 | nl.investing.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

September 15, 2026 | seekingalpha.com

Squarepoint Ops LLC Acquires 38,550 Shares of Rigel Pharmaceuticals, Inc. $RIGL

September 14, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) and Aclaris Therapeutics (NASDAQ:ACRS) Critical Contrast

September 11, 2026 | americanbankingnews.com

Bank of New York Mellon Corp Purchases Shares of 108,209 Rigel Pharmaceuticals, Inc. $RIGL

September 6, 2026 | marketbeat.com

Man Group plc Invests $814,000 in Rigel Pharmaceuticals, Inc. $RIGL

September 4, 2026 | marketbeat.com

Rigel to Participate in Upcoming September Investor Conferences

September 2, 2026 | prnewswire.com

Jupiter Topco LLC Invests $3.45 Million in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

Bank of America Corp DE Has $3.90 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

OMERS ADMINISTRATION Corp Invests $2.03 Million in Rigel Pharmaceuticals, Inc. $RIGL

August 27, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by Brokerages

August 26, 2026 | marketbeat.com

Globeflex Capital L P Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 24, 2026 | marketbeat.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, DSGN, RIGL, and CLYM Company Descriptions

Adagene NASDAQ:ADAG

$3.25 +0.04 (+1.34%)

As of 01:10 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Climb Bio NASDAQ:CLYM

$13.93 +0.29 (+2.13%)

As of 01:11 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Design Therapeutics NASDAQ:DSGN

$13.08 +0.53 (+4.19%)

As of 01:11 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$48.22 +1.13 (+2.40%)

As of 01:10 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, DSGN, RIGL, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, DSGN, RIGL, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, DSGN, RIGL, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, DSGN, RIGL, and CLYM Company Descriptions

Adagene NASDAQ:ADAG

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, DSGN, RIGL, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, DSGN, RIGL, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, DSGN, RIGL, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, DSGN, RIGL, and CLYM Company Descriptions

Adagene NASDAQ:ADAG

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools